Log in to save to my catalogue

Investigation of the Prognostic Value of TNF-[alpha] Gene Polymorphism among Patients Treated with I...

Investigation of the Prognostic Value of TNF-[alpha] Gene Polymorphism among Patients Treated with I...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_224634438

Investigation of the Prognostic Value of TNF-[alpha] Gene Polymorphism among Patients Treated with Infliximab, and the Effects of Infliximab Therapy on TNF-[alpha] Production and Apoptosis

About this item

Full title

Investigation of the Prognostic Value of TNF-[alpha] Gene Polymorphism among Patients Treated with Infliximab, and the Effects of Infliximab Therapy on TNF-[alpha] Production and Apoptosis

Publisher

Basel: S. Karger AG

Journal title

Pathobiology (Basel), 2004-01, Vol.71 (5), p.274

Language

English

Formats

Publication information

Publisher

Basel: S. Karger AG

More information

Scope and Contents

Contents

Objectives: Infliximab, a chimeric anti-tumor necrosis factor (TNF) antibody, is highly effective for the treatment of Crohn's disease (CD) and rheumatoid arthritis (RA). Our experiments focused on RA and CD patients receiving infliximab. Since cytokine production is largely determined by genetic factors, the promoter polymorphisms of TNF-[alpha] w...

Alternative Titles

Full title

Investigation of the Prognostic Value of TNF-[alpha] Gene Polymorphism among Patients Treated with Infliximab, and the Effects of Infliximab Therapy on TNF-[alpha] Production and Apoptosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_224634438

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_224634438

Other Identifiers

ISSN

1015-2008

E-ISSN

1423-0291

How to access this item